In addition to a reduction in levodopa dose, a dose reduction or discontinuation of monoamine oxidase (MAO)-B inhibitors or other dopaminergic drugs may be considered for patients with advanced PD who develop troublesome dyskinesia. This evidence concerns the gene MAOB and drug-induced dyskinesia.